A population‑scale molecular-clinical database built on dynamic, functional multi‑omics measures with longitudinal sampling, Sapient’s DynamiQ™ Insights Engine provides the mechanistically rich, human-relevant data needed to rapidly build evidence that advances the right biomarkers & targets – faster and with far greater certainty. Here’s how:
We use this reference dataset to confirm and contextualize disease & clinical links of biomarkers observed in studies.
We can cross‑validate targets and biomarkers identified in early studies in real‑world cohorts to confirm human relevance.
Our DynamiQ Tumor-Tissue virtual biobank enables rapid discovery of tractable, disease-modifying targets.
We can perform in-silico studies for biomarker scouting, hypothesis testing and generation, and independent validation of early findings.
Our large-scale, nontargeted datasets are ideal for training AI models on representative human physiological states.
Discover more with mechanistic context. Validate what others can only hypothesize.
We built DynamiQ to transform the pace and precision of drug development by grounding every insight in deeply phenotyped, real‑world human biology – helping programs move from hypotheses to human-validated evidence faster and with more confidence.
This multi-omics database acts as an insights engine to both generate de novo discoveries and to confirm the human relevance of targets and biomarkers observed in client studies – building mechanistic evidence to close translational gaps.
Need samples? No problem. We help you rapidly tap into our pre-characterized samples and/or the vast inventory of existing archival samples to accelerate your study timelines. Share your study needs with our team.
Purpose-built to uncover the dynamic drivers of disease and drug response, DynamiQ comprises:
Sapient’s DynamiQ multi-omics database is comprised of population‑scale human multi‑omics and clinical data, generated from >67,000 longitudinally collected plasma samples and complemented by diverse tumor and normal tissue samples.
The characterized samples are linked with EHR data, enabling biomarker discoveries to be correlated with real-world patient journeys.
In addition to our pre-characterized samples, Sapient’s DynamiQ Tumor-Tissue virtual biobank offers streamlined access to clinically annotated FFPE tumors and tissues across common and rare diseases.
With DynamiQ, Sapient is the only multi-omics partner that has the unique ability to both analyze your samples and validate the findings in independent real-world cohorts – as well as to uncover novel biology.
Whether used to contextualize disease and clinical links of biomarkers observed in your study, to validate early findings in independent patient cohorts, or to scout for targets and biomarkers without collecting new samples, we can leverage DynamiQ data in AI-powered analyses to build mechanistic evidence and in turn, your confidence in discoveries made.
DynamiQ’s database measures are enriched for metabolites, lipids, and proteins – the ultimate effectors of health and disease – to enable deep characterization of the dynamic molecular processes that modulate, or are modulated by, diseases and therapeutics.
By grounding discovery in real‑world human data, DynamiQ enables teams to rapidly confirm biomarker–disease links, evaluate clinical relevance, and strengthen confidence in early‑phase hypotheses.
See the exciting findings uncovered in this study using a DynamiQ virtual cohort to characterize changes in inflammatory markers observed following GLP-1 therapy.
DynamiQ™ is Sapient’s proprietary population‑scale molecular‑clinical database, comprised of metabolomic, lipidomic, proteomic, and clinical data generated in tens of thousands of human samples. It is designed to rapidly contextualize, validate, and prioritize biomarkers and targets using real‑world human evidence.
Access to DynamiQ is provided through guided analytical engagements with Sapient’s biocomputational team. Analyses are tailored to your objectives, with outputs designed to inform internal decisions and downstream experimental or translational strategies.
Our DynamiQ multi-omics database has representation across diverse demographics and diseases including:
You can book a guided demo using our DynamiQ Cohort Builder, where we can curate a proposed set of samples to analyze based on your biological question and therapeutic area of interest.
DynamiQ serves as a large‑scale reference dataset to confirm and contextualize disease and clinical links of biomarkers observed in your study. It enables cross‑validation in independent human cohorts, helping distinguish robust, human‑relevant signals from cohort‑specific findings.
Unlike many public repositories, DynamiQ is built from harmonized datasets generated using consistent analytical workflows and quality controls. This enables more reliable cross‑study comparisons, integrated multi‑omics analyses, and clinically meaningful interpretation.
Importantly, DynamiQ data goes beyond the genome, prioritizing dynamic molecular measures – proteins, metabolites, and lipids – that capture functional biology and treatment‑responsive changes not apparent from DNA or RNA alone. In fact, we have generated the most functional, dynamic molecular measures per sample, which are longitudinally collected and linked to detailed clinical, phenotypic, and outcome data.
This allows us to uncover dynamic drivers of disease and drug response and resolve phenotypic variability among individuals with similar genetic backgrounds, diagnoses, or lab values.
Our DynamiQ Tumor‑Tissue virtual biobank is comprised of tumor and normal tissue samples in which nontargeted proteomics measures (across 12,000+ protein groups) have been generated. The samples include clinically annotated FFPE tumors spanning common and rare cancer types, including breast, ovarian, kidney, colorectal, and pancreatic cancers. They also include normal human tissues to support differential analyses.
If you are seeking specific samples for your study, we can readily tap into the vast inventory of existing archival samples to streamline access for rapid study startup. If you have specific sample requirements, please reach out.
We can help you define a bespoke dataset from our multi-omics database alongside a biocomputational plan that delivers rapid time-to-insight to accelerate your study.
"*" indicates required fields
